Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2014
May 2014, Vol 5, No 4
May 2014, Vol 5, No 4
FGFR Inhibitor Shows Promising Anticancer Activity
By
Phoebe Starr
AACR Annual Meeting
May 2014, Vol 5, No 4
San Diego, CA—Inhibition of fibroblast growth factor receptors (FGFRs) 1, 2, 3, and 4 is showing promise in the treatment of cancers driven by FGFR alterations, especially bladder cancer and lung cancer, according to phase 1 studies presented at the 2014 American Association for Cancer Research annual meeting.
Read Article
Imbruvica (Ibrutinib) the First Bruton’s Tyrosine Kinase Inhibitor Approved for Treatment of Patients with Relapsed Chronic Lymphocytic Leukemia
By
Lisa A. Raedler, PhD, RPh
Drug Updates
May 2014, Vol 5, No 4
Chronic lymphocytic leukemia (CLL), the most common type of leukemia in adults, is a cancer of B-cell lymphocytes, which originate in the bone marrow, develop in the lymph nodes, and normally fight infection by producing an immune response.
Read Article
Treatment Paradigm for Lung Cancer Shifting Toward Targeted Therapies, Immunotherapy
By
Wayne Kuznar
Lung Cancer
,
Personalized Medicine
,
Solid Tumors
May 2014, Vol 5, No 4
Hollywood, FL—Driver mutations, most frequently KRAS and EGFR, account for approximately 50% of non–small-cell lung cancer (NSCLC), and this recognition is shifting the NSCLC treatment paradigm toward targeted therapy when possible, said Leora Horn, MD, MSc, Assistant Professor of Medicine, Division of Hematology/ Oncology, Vanderbilt University, Nashville, TN, at the 2014 National Comprehensive Cancer Network Conference.
Read Article
Contrast-Enhanced Ultrasound a Promising, Inexpensive Diagnostic Tool for Prostate Cancer
By
Rosemary Frei, MSc
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
May 2014, Vol 5, No 4
Stockholm, Sweden—An inexpensive, noninvasive imaging modality is proving successful for verifying the presence of prostate cancer.
Read Article
Advances in the Treatment of Patients with Castration-Resistant Prostate Cancer
By
Wayne Kuznar
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
May 2014, Vol 5, No 4
Hollywood, FL—The treatment options for patients with castration-resistant prostate cancer (CRPC) have increased over the past few years. Understanding the clinical disease states is essential when choosing therapy for this patient population, according to Celestia S. Higano, MD, Professor of Medicine and Urology, University of Washington, Seattle, who described the recent additions to the therapeutic armamentarium at the 2014 National Comprehensive Cancer Network Conference.
Read Article
Updated NCCN Survivorship Guidelines
By
Wayne Kuznar
Survivorship
,
Policies & Guidelines
May 2014, Vol 5, No 4
Hollywood, FL—Cancer survivorship guidelines have been expanded to include the management of neuropathic pain and cancer-associated cognitive dysfunction, said speakers at the 2014 National Comprehensive Cancer Network (NCCN) meeting.
Read Article
Survivorship Care Plan Use Lagging
By
Rosemary Frei, MSc
Survivorship
,
Survivorship Care
,
Policies & Guidelines
May 2014, Vol 5, No 4
Cancer centers are ramping up their efforts to create survivorship care plans (SCPs) for all of their patients. However, according to a new survey conducted in 2013, they still have far to go before January 1, 2015, when the American College of Surgeons Commission on Cancer (CoC) accreditation requirement of creating SCPs for all patients comes into effect (Birken SA, et al.
J Cancer Educ
. 2014 April 6. Epub ahead of print)
Read Article
Emerging Targeted Therapies for Advanced Pancreatic Cancer Show Promise
By
Wayne Kuznar
Pancreatic Cancer
May 2014, Vol 5, No 4
San Francisco, CA—New cytotoxic combinations introduced over the past several years for the treatment of advanced pancreatic adenocarcinoma now constitute the standard of care for the treatment of all stages of the disease. Eileen M. O’Reilly, MD, Gastrointestinal Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York, reviewed emerging treatments at the 2014 Gastrointestinal Cancers Symposium.
Read Article
Large Study Supports Regionalization of Gynecologic Cancer Care
By
Charles Bankhead
Society of Gynecologic Oncology
May 2014, Vol 5, No 4
Tampa, FL—Women with gynecologic cancers had significantly better survival when treated at high-volume centers, according to a review of 863,000 cases reported at the 2014 Society of Gynecologic Oncology meeting.
Read Article
Preventive Oophorectomy May Not Eliminate Risk for BRCA1-Related Uterine Cancer
By
Charles Bankhead
Society of Gynecologic Oncology
May 2014, Vol 5, No 4
Tampa, FL—Prophylactic salpingo-oophorectomy did not eliminate the risk for a rare but aggressive form of uterine cancer in women with BRCA1 mutations, according to a study reported at the 2014 Society of Gynecologic Oncology meeting.
Read Article
Page 1 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma